Bot­u­lism risk: FDA de­liv­ers warn­ing let­ter to Gadal Labs for site mak­ing OTC pe­di­atric drugs 

Gadal Lab­o­ra­to­ries has re­ceived an FDA warn­ing let­ter be­cause of sev­er­al man­u­fac­tur­ing vi­o­la­tions that in­creased the risk of bac­te­r­i­al con­t­a­m­i­na­tion to its over-the-counter (OTC) drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.